Must Reads by Date
Must reads for theWeek ending October 7, 2018
CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9
VTE risk for continuous cycle oral contraceptives, Li J et al. JAMA Intern Med. 2018 Oct 1. doi:10.1001/jamainternmed.2018.4251
auto-FMT could help ease GVHD after transplant, Taur Y et al. Sci Transl Med. 2018 Sep 26. doi: 10.1126/scitranslmed.aap9489
Low arginine linked to SFTS, Li X-K et al. Sci Transl Med. doi: 10.1126/scitranslmed.aat4162
Must reads for theWeek ending September 2, 2018
Osteoporosis tied to mortality risk in women with multiple myeloma, Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.
ctDNA may predict survival, treatment response in DLBCL, Kurtz DM et al. J Clin Oncol. 2018 Aug 20. doi: 10.1200/JCO.2018.78.5246.
Post-discharge rivaroxaban does not change VTE risk, Spyropoulos AC et al. N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1805090.
Restrictive transfusion strategy in CV surgery doesn't raise long-term risk, Mazer CD et al. N Engl J Med. 2018 Aug 26. doi:10.1056/NEJMoa1808561
Promise of SGN-CD70A against NHL eclipsed by adverse events, Phillips T et al. Invest New Drugs. 2018 Aug 22. doi: 10.1007/s10637-018-0655-0.
Must reads for theWeek ending August 26, 2018
Rituximab maintenance leads to better MCL outcomes, Vidal L et al. HemaSphere. 2018 Aug;2(4):e136.
CBC outperforms D-dimer in predicting DVT, The annual meeting of the American College of Physicians
Multidisciplinary care shortens hospital stay in sickle cell disease, Annual symposium of the Foundation for Sickle Cell Disease Research
CAR T signaling strength analyzed in preclinical study, Salter AI et al., Sci Signal. 2018 Aug 21;11. pii:eaat6753.
Obinutuzumab plus venetoclax compares well with established CLL therapies, Cramer P et al. Lancet Oncol. 2018 Aug 13. doi: 10.1016/S1470-2045(18)30414-5.
Must reads for theWeek ending August 19, 2018
Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA
Cleveland institutions to study CAR-T in Non-Hodgkin lymphoma, University Hospitals Cleveland Medical Center press statement
Caution urged over real-world bleeding risk with ibrutinib, Kunk PR et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 15. doi: 10.1016/j.clml.2018.07.287